Pfizer Inc. (NYSE:PFE) Shares Bought by CX Institutional

CX Institutional increased its stake in Pfizer Inc. (NYSE:PFE) by 5.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 109,858 shares of the biopharmaceutical company’s stock after acquiring an additional 5,627 shares during the period. CX Institutional’s holdings in Pfizer were worth $3,163,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of PFE. Worth Asset Management LLC acquired a new stake in shares of Pfizer in the first quarter valued at $29,000. Briaud Financial Planning Inc acquired a new stake in Pfizer in the third quarter valued at $30,000. GoalVest Advisory LLC raised its stake in Pfizer by 304.9% in the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 811 shares in the last quarter. Mizuho Securities Co. Ltd. acquired a new stake in Pfizer in the third quarter valued at $34,000. Finally, VisionPoint Advisory Group LLC raised its stake in Pfizer by 52,350.0% in the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 1,047 shares in the last quarter. 68.05% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

PFE has been the topic of a number of analyst reports. Barclays cut their price target on Pfizer from $34.00 to $28.00 and set an “equal weight” rating on the stock in a research note on Thursday, December 14th. Truist Financial cut their price target on Pfizer from $42.00 to $36.00 and set a “buy” rating on the stock in a research note on Thursday, December 14th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a report on Friday, March 1st. Guggenheim began coverage on Pfizer in a report on Friday, February 23rd. They set a “buy” rating and a $36.00 price objective on the stock. Finally, UBS Group dropped their price objective on Pfizer from $34.00 to $27.00 and set a “neutral” rating on the stock in a report on Thursday, December 14th. Twelve investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, Pfizer has an average rating of “Hold” and a consensus price target of $36.88.

Pfizer Stock Performance

NYSE:PFE traded down $0.30 during mid-day trading on Friday, reaching $27.36. The stock had a trading volume of 28,790,791 shares, compared to its average volume of 44,390,602. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91. The firm has a market capitalization of $154.93 billion, a price-to-earnings ratio of 76.00, a PEG ratio of 1.24 and a beta of 0.61. Pfizer Inc. has a twelve month low of $25.61 and a twelve month high of $42.22. The business has a 50 day simple moving average of $27.53 and a 200 day simple moving average of $29.70.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. The firm had revenue of $14.25 billion during the quarter, compared to the consensus estimate of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The firm’s revenue was down 41.3% compared to the same quarter last year. During the same quarter last year, the firm earned $1.14 earnings per share. On average, analysts expect that Pfizer Inc. will post 2.22 earnings per share for the current fiscal year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.